复星医药(02196.HK)子公司注射用奈达铂注册申请获受理 瞄准头颈癌等大癌种

Core Viewpoint - Fosun Pharma's subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of injectable Nedaplatin by the National Medical Products Administration, indicating progress in the company's drug development pipeline [1]. Group 1 - The drug Nedaplatin is a self-developed chemical medication by the group [1]. - It is intended for the treatment of various cancers, including head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular cancer, ovarian cancer, and cervical cancer [1].